Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier and get daily trading ideas and historical data downloads. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Vistagen Therapeutics Inc (VTGN)

Vistagen Therapeutics Inc (VTGN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 22,643
  • Shares Outstanding, K 39,620
  • Annual Sales, $ 490 K
  • Annual Income, $ -51,420 K
  • EBIT $ -70 M
  • EBITDA $ -70 M
  • 60-Month Beta 0.29
  • Price/Sales 44.49
  • Price/Cash Flow N/A
  • Price/Book 0.42
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -1.89
  • Most Recent Earnings $-0.45 on 02/12/26
  • Next Earnings Date 06/16/26
  • Annual Dividend & Yield (Fwd) 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sector Medical
  • INDUSTRY GROUPING Medical - Biomedical

Options Overview Details

View History
  • Implied Volatility 473.46% (+145.76%)
  • Historical Volatility 67.32%
  • IV Percentile 96%
  • IV Rank 66.31%
  • IV High 676.68% on 03/19/26
  • IV Low 73.56% on 08/01/25
  • Expected Move (DTE 16) 0.1105 (18.40%)
  • Put/Call Vol Ratio 0.00
  • Today's Volume 1,044
  • Volume Avg (30-Day) 331
  • Put/Call OI Ratio 0.03
  • Today's Open Interest 16,998
  • Open Int (30-Day) 17,206
  • Expected Range 0.4901 to 0.7111

Analyst Rating / Earnings Estimates

Current Rating
See More
Hold
Based on 6 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/26
See More
  • Average Estimate $-0.42
  • Number of Estimates 2
  • High Estimate $-0.37
  • Low Estimate $-0.47
  • Prior Year $-0.43
  • Growth Rate Est. (year over year) +2.33%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.5400 +11.22%
on 03/31/26
0.6700 -10.36%
on 03/17/26
+0.0146 (+2.49%)
since 02/27/26
3-Month
0.4300 +39.67%
on 02/13/26
0.7670 -21.69%
on 01/07/26
-0.0613 (-9.26%)
since 12/31/25
52-Week
0.4300 +39.67%
on 02/13/26
5.1400 -88.32%
on 11/24/25
-1.7394 (-74.33%)
since 04/01/25

Most Recent Stories

More News
CLASS ACTION DEADLINE TONIGHT MONDAY, MARCH 16: Faruqi & Faruqi, LLP Reminds Vistagen Therapeutics Investors of the Securities Class Action Lawsuit Deadline Tonight

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered In Vistagen To Contact Him Directly To Discuss Their Options...

VTGN : 0.6006 (+5.09%)
VTGN Investors Have Opportunity to Lead Vistagen Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm

LOS ANGELES , March 16, 2026 /PRNewswire/ -- The Schall Law Firm , a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Vistagen Therapeutics, Inc....

VTGN : 0.6006 (+5.09%)
VTGN Deadline: VTGN Investors Have Opportunity to Lead Vistagen Therapeutics, Inc. Securities Fraud Lawsuit

NEW YORK , March 16, 2026 /PRNewswire/ --

VTGN : 0.6006 (+5.09%)
Vistagen Therapeutics, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - VTGN

LOS ANGELES , March 16, 2026 /PRNewswire/ -- The DJS Law Group reminds investors of a class action lawsuit against Vistagen Therapeutics, Inc. ("Vistagen" or "the Company") (NASDAQ: VTGN ...

VTGN : 0.6006 (+5.09%)
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Vistagen Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadlines - VTGN

NEW YORK , March 12, 2026 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Vistagen Therapeutics, Inc. ("Vistagen" or the "Company") (NASDAQ: VTGN). Such...

VTGN : 0.6006 (+5.09%)
VTGN Investors Have Opportunity to Lead Vistagen Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm

LOS ANGELES , March 12, 2026 /PRNewswire/ -- The Schall Law Firm , a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Vistagen Therapeutics, Inc....

VTGN : 0.6006 (+5.09%)
Vistagen Therapeutics, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - VTGN

LOS ANGELES , March 12, 2026 /PRNewswire/ -- The DJS Law Group reminds investors of a class action lawsuit against Vistagen Therapeutics, Inc. ("Vistagen" or "the Company") (NASDAQ: VTGN ...

VTGN : 0.6006 (+5.09%)
VTGN SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Reminds Vistagen Therapeutics (VTGN) Investors of Securities Class Action Deadline on March 16, 2026

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered In Vistagen To Contact Him Directly To Discuss Their Options

VTGN : 0.6006 (+5.09%)
Class Action Filed Against Vistagen Therapeutics, Inc. (VTGN) - March 16, 2026 Deadline to Join - Contact Levi & Korsinsky

NEW YORK , March 11, 2026 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Vistagen Therapeutics, Inc. ("Vistagen" or the "Company") (NASDAQ: VTGN) of a class action securities lawsuit....

VTGN : 0.6006 (+5.09%)
LEVI & KORSINSKY, LLP ADVISORY TO INSTITUTIONAL INVESTORS: CLASS ACTION AGAINST VISTAGEN THERAPEUTICS MAY IMPACT PORTFOLIO HOLDINGS

NEW YORK , March 11, 2026 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Vistagen Therapeutics, Inc. (NASDAQ: VTGN) that a class action lawsuit has been filed on behalf of shareholders...

VTGN : 0.6006 (+5.09%)

Business Summary

VistaGen Therapeutics, Inc. is a biotechnology company. It is engaged in developing and commercializing product candidates for diseases and disorders involving the central nervous system. The company's lead product candidate consists of AV-101, is an orally available prodrug candidate in Phase II development,...

See More

Key Turning Points

3rd Resistance Point 0.6616
2nd Resistance Point 0.6435
1st Resistance Point 0.6221
Last Price 0.6006
1st Support Level 0.5826
2nd Support Level 0.5645
3rd Support Level 0.5431

See More

52-Week High 5.1400
Fibonacci 61.8% 3.3408
Fibonacci 50% 2.7850
Fibonacci 38.2% 2.2292
Last Price 0.6006
52-Week Low 0.4300

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.